

AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows. Additions are shown underlined, and deletions are shown ~~stricken through~~. Please amend paragraphs [0143], [0147] and [0149-0153], [0171], [0174] and [0239] as follows:

[0143] N-{4-[5-(4-~~cyclohexylamino~~cyclohexylamido-phenyl)-1H-imidazol-2-yl]-phenyl}-cyclohexylamide (24). To a solution of 2,4-di(4-aminophenyl)-1H-imidazole (23) (82 mg, 0.32 mmol) in pyridine (5 mL) was added cyclohexane carboxylic acid chloride (2 eq, 86 μ L, 94 mg, 0.64 mmol) and the mixture stirred at room temperature under inert atmosphere for 18h. The mixture was poured into H₂O (125 mL) and stirred for 25 min. The resulting yellow precipitate was collected by filtration (97 mg) and a portion (40 mg) purified by flash chromatography over silica using CH₂Cl₂/CH₃OH (19:1) as eluent to give the product as a pale yellow solid (20 mg, 0.085 mmol, 27%). mp 335-337 C, ¹H-NMR (500 MHz, DMSO-d₆) δ 12.37 (apparent d, 1H), 9.85 (apparent d, 2H), 7.88 (d, 2H, J=8.64 Hz), 7.75 (d, 2H, J=8.66 Hz), 7.69 (d, 2H, J=8.45 Hz), 7.66 (apparent d), 7.60 (d, 2H, J= 8.59), 2.34 (m, 2H), 1.78 (m, 8H), 1.66 (m, 3H), 1.42 (m, 4H), 1.26 (m, 6H); M/z = 471.6 (M⁺); TLC silica R_f=0.43 19:1 dichloromethane/methanol; Anal. (C₂₉H₃₄N₄O₂) C, H, N

[0147] N-{4-[5-(4-~~adamantylamino~~adamantylamido-phenyl)-1H-imidazol-2-yl]-phenyl}-adamantylamide (36). To a solution of 4-(2-(4-aminophenyl)-1H-imidazol-5-yl)benzenamine (35) (283 mg, 1.13 mmol) in dry pyridine (15 mL) was added adamantancarbonyl chloride (2.1 eq, 472 mg, 2.4 mmol) and the mixture stirred at room temperature for 18h and then diluted with H₂O (55 mL). The resulting solid was collected by filtration, dried and purified by chromatography over silica (dichloromethane/methanol, 0-5% gradient, 30 min.) giving the product as a tan solid (95mg, 0.17 mmol, 15%) Mp: 382°C. ¹H NMR (500 MHz, DMSO-d₆) δ 12.44 (apparent d, 1H), 9.23(s, 1H), 9.10 (s, 1H), 7.91 (m, 2H), 7.65 (m, 4H), 2.03(bs, 4H), 1.92 (bs, 9H), 1.71(bs, 9H). EIMS m/z M⁺ 575.5. Anal. (C, H, N, +1 CH₃OH)

[0149] N-{4-[5-(4-~~cycloheptylamino~~cycloheptylamido-phenyl)-1H-imidazol-2-yl]-phenyl}-cycloheptylamide. Product as a brown solid (15mg, 0.03 mmol, 2.7%) Mp: 318-320°C. ¹H NMR (500 MHz, DMSO-d₆) δ 12.37 (apparent d, 1H), 9.90(s, 1H), 9.76 (s, 1H), 7.88

Appl. No. : 10/821,667
Filed : April 9, 2004

(d, J=9Hz, 2H), 7.74 (d, J=9Hz 2H), 7.66(m, 6H), 1.92 (bs, 9H), 1.86-1.45 (m, 26H). EIMS m/z M^{+1} 499.6. Anal. (C, H, N, +2 H₂O)

[0150] N-{4-[2-(4-(4-fluorobenzoylamino)fluorobenzoylamido)-phenyl]-3H-imidazol-4-yl]-phenyl}-4-fluoro-benzamide. Product as a green solid (18 mg, 0.04 mmol, 1.3%) Mp: 345°C dec. ¹H NMR (400 MHz, DMSO-d₆) δ10.36 (apparent d, 2H), 8.06(m, 4H), 8.0 (m, 1H), 7.88 (m, 4H), 7.78 (m, 3H), 7.4 (m, 4H). EIMS m/z M^{+1} 495.4. Anal. (C, H, N)

[0151] N-{4-[5-(4-cyclohexylaminocyclohexylamido)-phenyl]-1H-imidazol-2-yl]-phenyl}-cyclohexylamide. Product as a yellow solid (95mg, 0.04 mmol, 13%) Mp: 335-337°C. ¹H NMR (500 MHz, DMSO-d₆) δ12.43 (apparent d, 1H), 9.92(s, 1H), 9.9.78 (s, 1H), 7.91 (m, 1H), 7.71 (dd, J=5Hz, 30Hz, 4H), 7.66 (m, 4H), 2.36 (m, 1H), 1.78(m, 3H), 1.65(m, 1H), 1.42(m, 2H), 1.26(m, 3H). EIMS m/z M^{+1} 471.3. Anal. (C, H, N)

[0152] N-{4-[2-(4-(2,4-dichlorobenzoylamino)dichlorobenzoylamido)-phenyl]-3H-imidazol-4-yl]-phenyl}-2,4-dichloro-benzamide. Product as a green solid (36 mg, 0.06 mmol, 1.9%) Mp: 310°C. ¹H NMR (400 MHz, DMSO-d₆) δ12.6 (1, 2H), 8.06(m, 4H), 10.54 (s, 1H), 10.42 (s, 1H), 8.42 (m, 2H), 7.9 (m, 4H), 7.86 (m, 5H), 7.82 (m, 2H), 7.73 (m, 1H). EIMS m/z M^{+1} 595.9. Anal. (C, H, N)

[0153] N-{4-[5-(4-(2-methylcyclohexyl)-amineamido)-phenyl]-1H-imidazol-2-yl]-phenyl}-(2-methylcyclohexyl)-amide. Product as a brown solid (32mg, 0.06 mmol, 1.3%) Mp: 195-199°C. ¹H NMR (400 MHz, DMSO-d₆) δ12.46 (apparent d, 1H), 9.88(dd, 1H), 9.78 (d, J=70Hz, 1H), 7.94 (dd, J=10Hz, 70Hz, 1H), 7.89 (dd, J=15Hz, 70Hz, 4H), 7.63 (m, 6H), 2.53 (m, 2H), 2.12(m, 2H), 1.71(m, 8H), 1.50(m, 6H), 1.30(m, 5H), 0.90(d, J=10Hz, 3H), 0.84(d, J=5Hz, 2H). EIMS m/z M^{+1} 499.4. Anal. (C, H, N)

[0171] 2-Methyl-cyclohexanecarboxylic acid {4-[5-(4-cyclohexylamino) cyclohexylamido)-phenyl]-1H-imidazol-2-yl]-phenyl}-amide (88). To a solution of Cyclohexanecarboxylic acid-{4-[2-(4-nitro-phenyl)-3H-imidazol-4-yl]-phenyl}-amide (86) (0.36 g, 1.0 mmol) in methanol/THF (10 mL; 1 mL) was added Raney nickel and the solution vacuum purged 5x with H₂ gas. The mixture was stirred under H₂ for 3.5h and filtered through celite and concentrated under reduced pressure to give a brown foam solid residue that was used as is in the coupling step.

Appl. No. : 10/821,667
Filed : April 9, 2004

[0174] N-{4-[5-(4-(2-methylcyclohexyl)-aminoamido-phenyl)-1H-imidazol-2-yl]-phenyl}-(4-methylcyclohexyl)-amide. Reverse phase chromatography over C18 using H₂O/ACN/TFA as eluent to yield the product as a tan solid (132mg, 0.26 mmol, 32%) Mp: 205-209°C. ¹H NMR (400 MHz, DMSO-d₆) δ12.43 (bs, 1H), 9.85(m, 2H), 7.89 (d, J=4Hz, 2H), 7.69 (m, 8H), 2.56 (m, 1H), 2.42 (m, 1H), 2.1 (m, 1H), 1.70(m, 8H), 1.55(m, 12H), 0.94(m, 8H). EIMS *m/z* M⁺ 499.6. Anal. (C, H, N)

[0239] N-Adamantan-2-yl-4-[2-[4-(cyclohexanecarbonyl-aminoamido)-phenyl]-3H-imidazol-4-yl]-benzamide. Product as a white solid. (59 mg, 0.113 mmol, 11%) Mp: 331°C. ¹H NMR (400 MHz, DMSO-d₆) δ12.59 (bs, 1H), 9.94 (s, 1H), 7.89 (m, 9H), 7.70 (d, J=8.4Hz, 3H), 4.05 (m, 1H), 2.35 (m, 1H), 2.14 (m, 2H), 2.00 (bs, 2H), 1.79 (m, 14H), 1.66 (m, 1H), 1.53 (d, J=12Hz, 2H), 1.42 (m, 2H), 1.26 (m, 4H). EIMS *m/z* M⁺ 523.6. Anal. (C, H, N)